DC-CIK生物免疫疗法联合化疗对甲状腺癌患者术后免疫功能及预后的影响研究  

Effect of DC-CIK biological immunotherapy combined with chemotherapy on postoperative immune function and prognosis of patients with thyroid cancer

作　　者：李超 柯清华[2] LI Chao;KE Qing-hua(Department of Pharmacy,Jingmen Duodao People's Hospital,Jingmen Hubei 448000,China;不详)

机构地区：[1]荆门市掇刀人民医院药剂科,湖北荆门448000 [2]荆门市第一人民医院药剂科,湖北荆门448000

出　　处：《中国处方药》2021年第11期163-165,共3页Journal of China Prescription Drug

摘　　要：目的分析树突状细胞(DC)-杀伤细胞(CIK)生物免疫疗法联合化疗对甲状腺癌患者术后免疫功能及预后的影响。方法选取2018年6月~2020年6月收治的甲状腺癌患者118例,采取随机数表法分为对照组与观察组,各59例,对照组术后实施CMF化疗辅助治疗,观察组在对照组基础上实施DC-CIK生物免疫疗法辅助治疗,对比两组临床疗效、治疗前后外周血T细胞亚群水平、抑制性受体在CD8^(+)T细胞、CD4^(+)T细胞上的表达水平。结果观察组的临床总缓解率要明显高于对照组,差异有统计学意义(P<0.05)。与对照组治疗后相比,观察组治疗后CD3^(+)、CD3^(+)CD4^(+)及CD4^(+)/CD8^(+)水平均升高,CD4^(+)CD25^(+)降低,差异有统计学意义(P<0.05)。与对照组相比,观察组抑制性受体PD-1、Tim-3在CD8^(+)T细胞、CD4^(+)T细胞上的表达水平较低,抑制性受体TIGIT在CD8^(+)T细胞、CD4^(+)T细胞上的表达水平较高,差异有统计学意义(P<0.05)。结论DC-CIK生物免疫疗法联合化疗可有效促进改善甲状腺癌患者术后免疫功能指标,在改善预后方面具有重要意义。Objective To explore and analyze the effects of DC-CIK biological immunotherapy combined with chemotherapy on postoperative immune function and prognosis of thyroid cancer patients.Methods 118 patients with thyroid cancer from June 2018 to June 2020 were selected as obiects,all the patients were divided into the control group and the observation group by random number table,there were 59 cases in each group.The control group was given CMF chemotherapy adjuvant treatment after surgery,and on the basis of control group,the observation group was given the implementation of DC-CIK biological immunotherapy adjuvant treatment.The clinical efficacy,the level of peripheral blood T cell subsets before and after treatment,and the expression level of inhibitory receptors on CD8^(+)T cells and CD4^(+)T cells was compared in the two groups.Results The total clinical remission rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).Compared with the control group after treatment,the observation group's CD3^(+),CD3^(+)CD4^(+)and CD4^(+)/CD8^(+)levels increased after treatment,and CD4^(+)CD25^(+)decreased,and the differences were statistically significant(P<0.05).Compared with the control group,the expression levels of inhibitory receptor PD-1 and Tim-3 in the observation group on CD8^(+)T cells and CD4^(+)T cells were lower,and the expression of inhibitory receptor TIGIT on CD8^(+)T cells and CD4^(+)T cells were high,and the differences were statistically significant(P<0.05).Conclusion DC-CIK biological immunotherapy combined with chemotherapy can effectively promote the improvement of postoperative immune function indexes in patients with thyroid cancer,which have the great significance in improving the prognosis.

关 键 词：DC-CIK生物免疫疗法 化疗 甲状腺癌 免疫功能 预后 

分 类 号：R736.1[医药卫生—肿瘤]